Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - solution for injection - flecainide acetate 10 mg/ml - cardiac therapy

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pi pharma sa-nv - flecainide acetate 100 mg - tablet - flecainide

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - solution for injection/infusion - flecainide acetate 10 mg/ml - cardiac therapy

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

60's (30's blister x 2) -

Namibia - English - Namibia Medicines Regulatory Council

inova pharmaceuticals (pty) ltd - flecainide acetate - tablets - flecainide acetate tablets 100mg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

eisai co., ltd. - flecainide acetate - white fine granule

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

eisai co., ltd. - flecainide acetate - white tablet (φ: 8.6 mm, thickness: 4.5 mm)

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

eisai co., ltd. - flecainide acetate - white tablet (φ: 7.1 mm, thickness: 3.3 mm)

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

eisai co., ltd. - flecainide acetate - injection

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; hydrogenated vegetable oil; magnesium stearate; pregelatinised maize starch; croscarmellose sodium - 1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes. b) due to dual av nodal pathways in patients with debilitating symptoms. c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. although flecacor may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecacor should be used with extreme caution, preferably after other anti-arrhythmic drugs have been tried or considered inappropriate. use of flecacor in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. life threatening ventricular arrhythmias not controlled by other drugs. intravenous flecainide(available as tambocor injection) is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requirement. all use of the injection should be in hospitals only. flecacor tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means. prescribers should also consult the "precautions" section of this product information.